MA53124B1 - Agents de dégradation sélectifs des récepteurs des oestrogènes - Google Patents
Agents de dégradation sélectifs des récepteurs des oestrogènesInfo
- Publication number
- MA53124B1 MA53124B1 MA53124A MA53124A MA53124B1 MA 53124 B1 MA53124 B1 MA 53124B1 MA 53124 A MA53124 A MA 53124A MA 53124 A MA53124 A MA 53124A MA 53124 B1 MA53124 B1 MA 53124B1
- Authority
- MA
- Morocco
- Prior art keywords
- estrogen receptor
- selective estrogen
- receptor degraders
- degraders
- serd
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Finger-Pressure Massage (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
Abstract
L'invention concerne de nouveaux agents de dégradation sélectifs des récepteurs des oestrogènes (serd) selon la formule :, des sels pharmaceutiquement acceptables de ceux-ci, et des compositions pharmaceutiques de ceux-ci, formule dans laquelle l'un parmi r1 et r2 est indépendamment choisi parmi cl, f, -cf3 ou -ch3, et l'autre est l'hydrogène, et des procédés pour leur utilisation.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862697100P | 2018-07-12 | 2018-07-12 | |
| PCT/US2019/041334 WO2020014435A1 (fr) | 2018-07-12 | 2019-07-11 | Agents de dégradation sélectifs des récepteurs des oestrogènes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA53124A MA53124A (fr) | 2021-05-19 |
| MA53124B1 true MA53124B1 (fr) | 2023-02-28 |
Family
ID=67470734
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA53124A MA53124B1 (fr) | 2018-07-12 | 2019-07-11 | Agents de dégradation sélectifs des récepteurs des oestrogènes |
| MA53126A MA53126B1 (fr) | 2018-07-12 | 2019-07-11 | Agents de dégradation sélectifs du récepteur des oestrogènes |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA53126A MA53126B1 (fr) | 2018-07-12 | 2019-07-11 | Agents de dégradation sélectifs du récepteur des oestrogènes |
Country Status (37)
| Country | Link |
|---|---|
| US (4) | US10654866B2 (fr) |
| EP (2) | EP3820873B1 (fr) |
| JP (6) | JP6995241B2 (fr) |
| KR (3) | KR102589886B1 (fr) |
| CN (2) | CN112638916B (fr) |
| AR (2) | AR115694A1 (fr) |
| AU (2) | AU2019299947B2 (fr) |
| BR (1) | BR122023025061A2 (fr) |
| CA (1) | CA3105501C (fr) |
| CL (1) | CL2021000045A1 (fr) |
| CO (1) | CO2021000043A2 (fr) |
| CR (1) | CR20210007A (fr) |
| DK (1) | DK3820873T3 (fr) |
| EA (1) | EA202092975A1 (fr) |
| EC (1) | ECSP21001770A (fr) |
| ES (1) | ES2933980T3 (fr) |
| FI (1) | FI3820873T3 (fr) |
| HR (1) | HRP20230009T1 (fr) |
| HU (1) | HUE060963T2 (fr) |
| IL (3) | IL289871B2 (fr) |
| JO (1) | JOP20210005A1 (fr) |
| LT (1) | LT3820873T (fr) |
| MA (2) | MA53124B1 (fr) |
| MD (1) | MD3820873T2 (fr) |
| MX (2) | MX2021000375A (fr) |
| MY (1) | MY198962A (fr) |
| PE (1) | PE20210400A1 (fr) |
| PH (1) | PH12021550049A1 (fr) |
| PL (1) | PL3820873T3 (fr) |
| PT (1) | PT3820873T (fr) |
| RS (1) | RS63809B1 (fr) |
| SA (1) | SA521421008B1 (fr) |
| SG (1) | SG11202100148TA (fr) |
| SI (1) | SI3820873T1 (fr) |
| TW (1) | TWI702219B (fr) |
| UA (1) | UA127507C2 (fr) |
| WO (1) | WO2020014435A1 (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3355884T (lt) | 2015-10-01 | 2021-07-26 | Olema Pharmaceuticals, Inc. | Tetrahidro-1h-pirido[3,4-b]indolo antiestrogeniniai vaistai |
| SI3820874T1 (sl) * | 2018-07-12 | 2023-02-28 | Eli Lilly And Company | Selektivni razgrajevalci estrogenskih receptorjev |
| TWI702219B (zh) * | 2018-07-12 | 2020-08-21 | 美商美國禮來大藥廠 | 選擇性雌激素受體降解劑 |
| KR20220034129A (ko) | 2019-07-07 | 2022-03-17 | 올레마 파마슈티컬스 인코포레이티드 | 에스트로겐 수용체 길항제 요법 |
| US12545640B2 (en) | 2019-10-01 | 2026-02-10 | Sanofi | Substituted 6,7-dihydro-5H-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof |
| WO2021116074A1 (fr) | 2019-12-09 | 2021-06-17 | Sanofi | Forme cristalline d'un dérivé d'acide 7h-benzo[7]annulène-2-carboxylique |
| TW202146007A (zh) * | 2020-02-27 | 2021-12-16 | 法商賽諾菲公司 | 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合 |
| US20230404971A1 (en) * | 2020-11-23 | 2023-12-21 | Sanofi | Combination Comprising Abemaciclib and 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-Fluoropropyl)Pyrrolidin-3-yl]Oxyphenyl]-8,9-Dihydro-7H-Benzo[7]Annulene-2-Carboxylic Acid |
| WO2022177843A1 (fr) * | 2021-02-16 | 2022-08-25 | Genentech, Inc. | Traitement du cancer du sein à l'aide de polythérapies comprenant du gdc-9545 et de l'abémaciclib ou du ribociclib |
| CN114957114A (zh) * | 2021-02-26 | 2022-08-30 | 冷志 | 一种4-溴-3-氯-7-甲氧基喹啉的合成方法 |
| TWI837605B (zh) | 2021-03-09 | 2024-04-01 | 美商美國禮來大藥廠 | 使用serd組合給藥方案治療癌症之方法 |
| CN117042771A (zh) * | 2021-03-09 | 2023-11-10 | 伊莱利利公司 | 使用serd给药方案的组合治疗癌症的方法 |
| TWI894443B (zh) * | 2021-03-16 | 2025-08-21 | 美商美國禮來大藥廠 | 選擇性雌激素受體降解劑 |
| US11926634B2 (en) * | 2022-02-01 | 2024-03-12 | Eli Lilly And Company | Processes for the preparation of selective estrogen receptor degraders |
| KR20250089532A (ko) | 2022-10-17 | 2025-06-18 | 아스트라제네카 아베 | 암 치료를 위한 serd의 조합 |
| TWI863667B (zh) | 2022-11-02 | 2024-11-21 | 美商佩特拉製藥公司 | 用於治療疾病之磷酸肌醇3-激酶(pi3k)異位色烯酮抑制劑 |
| JP2025539034A (ja) | 2022-11-11 | 2025-12-03 | アストラゼネカ・アクチエボラーグ | 癌の治療のための併用療法 |
| US20240180893A1 (en) | 2022-11-17 | 2024-06-06 | Astrazeneca Ab | Methods of treatment of breast cancer |
| KR20260005985A (ko) | 2023-05-05 | 2026-01-12 | 일라이 릴리 앤드 캄파니 | Er+ 유방암을 갖는 대상체에서 중추 신경계 (cns) 전이를 치료 및 예방하는 데 사용하기 위한 임루네스트란트 또는 그의 염 |
| WO2024231548A1 (fr) | 2023-05-11 | 2024-11-14 | Astrazeneca Ab | Association d'un inhibiteur de parp1 et d'un agent de dégradation d'œstrogène sélectif pour le traitement du cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7056931B2 (en) * | 2001-05-22 | 2006-06-06 | Eli Lilly And Company | 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods |
| US7329654B2 (en) * | 2001-12-19 | 2008-02-12 | Janssen Pharmaceutica N.V. | Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators |
| EP1497277A1 (fr) * | 2002-04-19 | 2005-01-19 | Signal Pharmaceuticals, Inc. | Composes benzopyranone, compositions contenant ces composes et methodes de traitement associees |
| US20090023917A1 (en) * | 2004-01-22 | 2009-01-22 | Eli Lilly And Company | Selective Estrogen Receptor Modulators for the Treatment of Vasomotor Symptoms |
| US20080221163A1 (en) * | 2005-01-18 | 2008-09-11 | Jeffrey Alan Dodge | Selective Estrogen Receptor Modulators |
| MX2015016171A (es) | 2013-06-19 | 2016-08-08 | Seragon Pharmaceuticals Inc | Moduladores del receptor de estrogeno de azetidina y usos de los mismos. |
| IL311006A (en) * | 2014-12-18 | 2024-04-01 | Hoffmann La Roche | Tetrahydro-pyrido[3, 4-b]indole estrogen receptor modulators and their uses |
| JP6807841B2 (ja) | 2014-12-18 | 2021-01-06 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | エストロゲン受容体モジュレーター及びその使用 |
| WO2018108954A1 (fr) | 2016-12-12 | 2018-06-21 | F. Hoffmann-La Roche Ag | Procédé de préparation de 2-(3-(fluorométhyl)azétidin-1-yl)éthan-1-ol |
| SI3820874T1 (sl) * | 2018-07-12 | 2023-02-28 | Eli Lilly And Company | Selektivni razgrajevalci estrogenskih receptorjev |
| TWI702219B (zh) * | 2018-07-12 | 2020-08-21 | 美商美國禮來大藥廠 | 選擇性雌激素受體降解劑 |
-
2019
- 2019-07-02 TW TW108123257A patent/TWI702219B/zh active
- 2019-07-03 AR ARP190101886A patent/AR115694A1/es active IP Right Grant
- 2019-07-11 MY MYPI2021000056A patent/MY198962A/en unknown
- 2019-07-11 CN CN201980046849.3A patent/CN112638916B/zh active Active
- 2019-07-11 IL IL289871A patent/IL289871B2/en unknown
- 2019-07-11 US US16/508,745 patent/US10654866B2/en active Active
- 2019-07-11 PL PL19745925.8T patent/PL3820873T3/pl unknown
- 2019-07-11 SG SG11202100148TA patent/SG11202100148TA/en unknown
- 2019-07-11 UA UAA202100102A patent/UA127507C2/uk unknown
- 2019-07-11 CN CN202311312431.7A patent/CN117379428A/zh active Pending
- 2019-07-11 SI SI201930406T patent/SI3820873T1/sl unknown
- 2019-07-11 KR KR1020227044200A patent/KR102589886B1/ko active Active
- 2019-07-11 JO JOP/2021/0005A patent/JOP20210005A1/ar unknown
- 2019-07-11 RS RS20221142A patent/RS63809B1/sr unknown
- 2019-07-11 ES ES19745925T patent/ES2933980T3/es active Active
- 2019-07-11 PT PT197459258T patent/PT3820873T/pt unknown
- 2019-07-11 EA EA202092975A patent/EA202092975A1/ru unknown
- 2019-07-11 MX MX2021000375A patent/MX2021000375A/es unknown
- 2019-07-11 AU AU2019299947A patent/AU2019299947B2/en active Active
- 2019-07-11 KR KR1020237034781A patent/KR102783756B1/ko active Active
- 2019-07-11 MA MA53124A patent/MA53124B1/fr unknown
- 2019-07-11 MD MDE20210462T patent/MD3820873T2/ro unknown
- 2019-07-11 PE PE2020002017A patent/PE20210400A1/es unknown
- 2019-07-11 MA MA53126A patent/MA53126B1/fr unknown
- 2019-07-11 JP JP2021500536A patent/JP6995241B2/ja active Active
- 2019-07-11 DK DK19745925.8T patent/DK3820873T3/da active
- 2019-07-11 HU HUE19745925A patent/HUE060963T2/hu unknown
- 2019-07-11 WO PCT/US2019/041334 patent/WO2020014435A1/fr not_active Ceased
- 2019-07-11 FI FIEP19745925.8T patent/FI3820873T3/fi active
- 2019-07-11 HR HRP20230009TT patent/HRP20230009T1/hr unknown
- 2019-07-11 LT LTEPPCT/US2019/041334T patent/LT3820873T/lt unknown
- 2019-07-11 EP EP19745925.8A patent/EP3820873B1/fr active Active
- 2019-07-11 EP EP22201995.2A patent/EP4155310A1/fr active Pending
- 2019-07-11 KR KR1020217000466A patent/KR102550538B1/ko active Active
- 2019-07-11 CA CA3105501A patent/CA3105501C/fr active Active
- 2019-07-11 BR BR122023025061-3A patent/BR122023025061A2/pt not_active Application Discontinuation
- 2019-07-11 CR CR20210007A patent/CR20210007A/es unknown
-
2020
- 2020-05-18 US US16/876,819 patent/US11117902B2/en active Active
-
2021
- 2021-01-06 CO CONC2021/0000043A patent/CO2021000043A2/es unknown
- 2021-01-07 CL CL2021000045A patent/CL2021000045A1/es unknown
- 2021-01-08 PH PH12021550049A patent/PH12021550049A1/en unknown
- 2021-01-10 IL IL280065A patent/IL280065B/en unknown
- 2021-01-11 MX MX2023006047A patent/MX2023006047A/es unknown
- 2021-01-12 EC ECSENADI20211770A patent/ECSP21001770A/es unknown
- 2021-01-12 SA SA521421008A patent/SA521421008B1/ar unknown
- 2021-09-02 US US17/465,066 patent/US11634426B2/en active Active
- 2021-12-14 JP JP2021202668A patent/JP7009672B1/ja active Active
-
2022
- 2022-01-12 JP JP2022003022A patent/JP7241211B2/ja active Active
- 2022-06-08 AU AU2022203969A patent/AU2022203969B2/en active Active
- 2022-08-14 IL IL295598A patent/IL295598B2/en unknown
-
2023
- 2023-03-06 JP JP2023033486A patent/JP7557564B2/ja active Active
- 2023-03-15 US US18/121,667 patent/US11993608B2/en active Active
-
2024
- 2024-09-13 JP JP2024159222A patent/JP7746496B2/ja active Active
- 2024-11-22 AR ARP240103228A patent/AR134487A2/es unknown
-
2025
- 2025-09-17 JP JP2025154293A patent/JP2025186400A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA53124B1 (fr) | Agents de dégradation sélectifs des récepteurs des oestrogènes | |
| MA67365B1 (fr) | Dérivés de benzisoxazole sulfonamide | |
| MA31419B1 (fr) | Derives de pyridine | |
| TNSN08139A1 (fr) | Composes therapeutiques | |
| MA54653B1 (fr) | Modulateurs du récepteur de cxcr7 pipéridine | |
| BR112020001825A2 (pt) | compostos e métodos para a degradação direcionada de receptor de androgênio | |
| MA33467B1 (fr) | Promédicaments comprenant un conjugué insuline-lieur | |
| MA31766B1 (fr) | Composés organiques | |
| MA39043A1 (fr) | Dérivés de purine substitués en positions 2 et 6, et leur utilisation dans le traitement des désordres prolifératifs | |
| TNSN07275A1 (fr) | Derives de triazole substitues, servant d'antagonistes d'ocytocine | |
| EA200700099A1 (ru) | Производные пиридина | |
| SE0300119D0 (sv) | Novel compounds | |
| MA30999B1 (fr) | Composés. | |
| MA33533B1 (fr) | Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles | |
| MA33836B1 (fr) | Compositions pharmaceutiques contenant des ligands des récepteurs sigma | |
| MA56883B1 (fr) | Dérivés de 2-hydroxycycloalcane-1-carbamoyle | |
| MA49127B1 (fr) | Dérivés d'indole n-substitués | |
| TNSN08137A1 (fr) | Derives de carboxamides servant d'antagonistes des recepteurs muscariniques | |
| MA31761B1 (fr) | Nouveaux inhibiteurs de seh et leur utilisation | |
| MA34760B1 (fr) | Composés et leurs utilisation | |
| MA34553B1 (fr) | Combinaisons contenant du n-(2-arylamino)arylsulfonamide substitué | |
| MA41494B1 (fr) | Composés benzoxaborole substitués en position 4 et utilisations associées | |
| UA84896C2 (ru) | Производные гидронопола как агонисты человеческих рецепторов orl1 | |
| MA70477B1 (fr) | Composés amido hétéroaromatiques utiles dans le traitement de maladies hépatiques | |
| EP2202222A3 (fr) | Dérivés d'indène, leur préparation et leur utilisation en tant que médicaments |